CTOs on the Move

Silverback Therapeutics

www.silverbacktx.com

 
Silverback Therapeutics is charting a new path for treating a range of severe diseases. We are developing therapies that act on fundamental biological pathways that underlie disease, but that modern medicine has not been able to fully harness — until now.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

Silverback Therapeutics raised $78.5M on 03/11/2020
Silverback Therapeutics raised $85M on 09/23/2020

Similar Companies

Celularity

Celularity, headquartered in Florham Park, N.J., is a clinical stage biotechnology company leading the next evolution in cellular medicine by delivering off-the-shelf allogeneic placenta-derived cellular therapies at unparalleled scale, quality and economics. Celularity`s innovative approach to cell therapy harnesses the unique therapeutic potential locked within the postpartum placenta. Through nature`s immunotherapy engine – the placenta – Celularity is leading the next evolution of cellular medicine with placenta-derived T cells, NK cells, and pluripotent stem cells to target unmet and underserved clinical needs in cancer, infectious and degenerative diseases.

Phylagen

Phylagen is a venture-backed microbiome data analytics company that harnesses the vast, unseen world of microbes to improve business performance and make our lives better.

ABS Global

Headquartered in DeForest, Wisconsin, ABS Global is the world-leading provider of bovine genetics, reproduction`services, technologies and uddercare products.

CordenPharma

CordenPharma is a Boulder, CO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Generate Biomedicines

Generate Biomedicines is the first drug generation company, pioneering a machine learning-powered generative biology platform with the ability to generate new drugs on demand across a wide range of biologic modalities. The platform can drastically improve the speed at which targets and therapeutics are identified and validated, the specificity of target engagement by generated proteins, and the cost of identifying and developing clinical candidates. The company`s platform represents a potentially fundamental shift in what`s possible in the field of therapeutic development, addressing key challenges of drug discovery and drastically expanding the available search space for novel biomedicines. Generate Biomedicines was founded by Flagship Pioneering after two years of foundational research in its Labs unit and launched in 2020.